Platelet-Derived Biotherapies: From Blood Products to Neuroregenerative Medicine
The following article is a collaboration between members of the 2026 Neuronline Community Leaders program. The program is a group of active SfN members who are interested in cultivating the sharing and discussion of resources among SfN members on the Neuronline Community.
Platelets, also called thrombocytes, are small fragments of blood known for preventing bleeding and forming clots. Recent research has highlighted key features that platelets share with neurons. Like neurons, platelets carry neuromodulatory peptides, lipids, and RNAs, and can release components from granules or in extracellular vesicles. Platelet-derived biotherapies are exciting new clinical approaches that use platelets and their products, including lysates, supernatant concentrates, vesicles, and other components, to reduce inflammation and promote neuroprotection in preclinical models of neurological disorders, like neurodegeneration and traumatic brain injuries.
Platelet as Multimodal Neuroregenerative Platform - Abinaya Srinivasan
Neurological disorders are particularly difficult to treat because their progression rarely depends on a single pathological mechanism. Neuroinflammation, oxidative stress, synaptic dysfunction, and neuronal loss often occur together, while most conventional drugs are designed to act on a limited number of targets. An emerging translational approach is to harness the natural regenerative potential of human platelets. Beyond their familiar role in blood clotting, platelets contain growth factors, neurotrophic proteins, cytokines, antioxidants, and extracellular vesicles that participate in tissue repair and cellular communication (Burnouf & Walker, 2022).
Human Platelet Lysate and Extracellular Vesicles
Human platelet lysate (HPL) prepared from clinical-grade platelet concentrates has shown neuroprotective effects in experimental models of neurological disease. Early studies demonstrated that HPL protected neuronal cells exposed to oxidative and neurotoxic stress, including models relevant to Parkinson’s disease and amyotrophic lateral sclerosis (Gouel et al., 2017). This finding is notable because the therapeutic activity doesn’t depend on one recombinant growth factor, but rather on a combination of bioactive molecules.
Translational Potential and Future Challenges
Researchers have investigated the approach in more complex disease models. In experimental models of traumatic brain injury, platelet lysate treatment reduced neuroinflammation and oxidative damage and supported neurological recovery (Nebie et al., 2021). Platelet-derived extracellular vesicles are another important component of this research. These small vesicles carry proteins, lipids, and nucleic acids between cells and may contribute to the neuroprotective and neurorestorative properties of platelet preparations. Researchers have therefore developed methods to characterize and isolate extracellular vesicles from human platelet lysates for potential applications in neuroregenerative medicine (Nyam-Erdene et al., 2021).
To me, one of the most interesting translational aspects of this research is its starting material. Platelet concentrates are already collected worldwide under established blood-banking systems, and even platelet units that are no longer suitable for transfusion may retain biologically active molecules that can potentially be repurposed for regenerative applications (Burnouf & Goubran, 2022). However, moving from promising animal studies to patient treatment will require standardized manufacturing, measures to ensure pathogen safety, characterization of active components, preproperate delivery routes, and carefully designed clinical trials.
As a researcher working in regenerative neuroscience, I find this concept promising because it connects transfusion medicine, neuroscience, and biotechnology. Rather than focusing exclusively on replacing a single missing molecule, platelet-derived biotherapies may provide several complementary signals required by a neurodegenerative state in the brain. Further research will determine whether these encouraging preclinical findings can be translated into safe and reproducible treatments for patients, but they illustrate how researchers might repurpose an established medical resource for an entirely new therapeutic purpose.
Therapeutic Potential for Aging and Psychological Disorders - Soaleha Shams
Using platelet-derived biotherapies to reduce neuroinflammation, support neuronal and synaptic health, delay senescence, and treat mental illnesses is a somewhat speculative yet encouraging prospect. Platelet-rich plasma (PRP) in elderly mice can improve memory and locomotion (Demir & Karagoz, 2020), but no clinical studies have yet tested these hypotheses ethically and reliably in human populations. Similarly, platelets and platelet products may have potential applications in treating psychological disorders, and there is preclinical evidence of improved mood-related outcomes in rats given PRP (Ji et al., 2023), but these findings remain to be explored in clinical studies.
Compared with relatively predictable patterns of typical human aging, psychological disorders can be multifaceted and dynamic, and relevant affective and behavioral states can be complex and difficult to accurately capture using available preclinical models. Nonetheless, for treatment-resistant depression and other behavioral and stress disorders for which existing pharmacological treatments are inadequate, there is an immense need to find novel primary and adjuvant biotherapies. Neuroprotective effects of platelet-rich and platelet-derived acellular products already used in orthopedic and dermatologic applications may also improve neuroplasticity and cognition in contexts of social stress, isolation, and psychological trauma. Existing preclinical studies in neurorehabilitation have shown significant mitigation of cortical inflammation and protection of the blood-brain barrier after traumatic brain injury. Given the overlapping biochemical and immune pathways in traumatic brain injury and post-traumatic stress disorder and the frequent comorbidity of the two from a single acute event, these shared features provide another reason to investigate the physical and psychological effects of platelet-derived biotherapies.
Platelet count, volume, and ratios have already been examined in relation to social isolation and depression in humans, and lower platelet counts and platelet serotonin levels are reportedly linked to depression, self-harm, and suicidal behaviors (Liu et al., 2026). Besides carrying growth and immune factors, platelets serve as peripheral reservoirs of serotonin, which they store in granules after taking it up from plasma. Platelets also express serotonin receptors and could act as a relay between the brain and the body. These platelet features may be exploited in the future using omics-based assays and biomarkers to substantiate safety and therapeutic effects, optimize disease-specific and individualized treatments, and establish regulatory and manufacturing standards for psychological health and wellness.
Overcoming Bioavailability Deficiency in the Cerebral Microvasculature - Nguyen Nguyen
While the potential benefits of platelets and platelet-derived extracellular vesicles are promising, a major bottleneck limits their clinical translation: achieving sufficient local bioavailability in impaired regions of the brain (Lombardo et al., 2020). Even when the blood-brain barrier is compromised in neurodegenerative disorders or traumatic brain injury, rapid systemic clearance and local perfusion deficits can prevent sufficient concentrations of circulating biotherapies from reaching damaged brain tissue. Addressing this delivery challenge often requires techniques from biotransport engineering and fluid dynamics to help deliver platelet-derived carriers (Charoenphol et al., 2011).
In the cerebral microvasculature, natural hemodynamic forces push smaller particles, such as platelet extracellular vesicles, toward the vessel wall. By engineering non-spherical geometries such as discoidal particles, the carriers could leverage the hydrodynamic drift to concentrate the therapeutics along the cerebral endothelium, maximizing mass transport across the blood-brain barrier (Decuzzi et al., 2010; Cooley et al., 2018).
On a different note, I believe that the platelet-derived extracellular vesicles may offer advantages over other synthetic carriers because of their massive natural receptor-mediated biodocking from native platelet membrane glycoproteins like GPlb, P-selectin receptors, and integrins (Hu et al., 2015). The vesicle can target endothelial adhesion markers such as ICAM-1 and VCAM-1 that are overexpressed at injured sites to create a strong docking mechanism and prevent cerebral blood flow from simply washing the payload away before transcytosis occurs (Li et al., 2020).
To further ensure spatial control, engineering polymer cores encapsulated within platelet membranes to undergo mechanical deformation under elevated shear stress provides a powerful therapeutic avenue (Korin et al., 2012). This approach could release the neuroprotective payload from the platelet-derived extracellular vesicles exclusively at sites of microvascular occlusion or ischemic injury, sparing healthy tissue.
The ultimate success of platelet-derived biotherapies depends on both their biochemical potency and our ability to solve their transport and localization limits. By integrating platelet biomimicry with shear-directed fluid dynamics, active receptor docking, and stimuli-responsive release mechanisms, we may be able to transform standard blood products into targeted, intelligent neuro-delivery systems. Translating these preclinical strategies into clinical reality will demand that we establish standardized manufacturing, strictly characterize active vesicle fractions, optimize delivery routes, and thoroughly address safety profiles.
References
Burnouf T, Walker TL. The multifaceted role of platelets in mediating brain function. Blood.2022;140(8):815–827. doi:10.1182/blood.2022015970.
Charoenphol, Phapanin, et al. "Particle-cell dynamics in human blood flow: implications forvascular-targeted drug delivery." Journal of Biomechanics 45.16 (2012): 2822-2828.
Cooley, Michaela, et al. "Influence of particle size and shape on their margination andwall-adhesion: implications in drug delivery vehicle design across nano-to-micro scale."Nanoscale 10.32 (2018): 15350-15364.
Decuzzi, P., et al. "Size and shape effects in the biodistribution of intravascularly injectedparticles." Journal of Controlled Release 141.3 (2010): 320-327.
Gouel F, Do Van B, Chou ML, et al. The protective effect of human platelet lysate in models ofneurodegenerative disease: involvement of the Akt and MEK pathways. J Tissue EngRegen Med. 2017;11(11):3236–3240. doi:10.1002/term.2222.
Hu, Che-Ming J., et al. "Nanoparticle biointerfacing by platelet membrane cloaking." Nature526.7571 (2015): 118-121.
Korin, Netanel, et al. "Shear-activated nanotherapeutics for drug targeting to obstructed bloodvessels." Science 337.6095 (2012): 738-742.
Li, Mingxi, et al. "Platelet membrane biomimetic magnetic nanocarriers for targeted delivery andin situ generation of nitric oxide in early ischemic stroke." ACS nano 14.2 (2020):2024-2035.
Nebie O, Carvalho K, Barro L, et al. Human platelet lysate biotherapy for traumatic brain injury:preclinical assessment. Brain. 2021;144(10):3142–3158.
Nyam-Erdene A, Nebie O, Delila L, et al. Characterization and chromatographic isolation ofplatelet extracellular vesicles from human platelet lysates for applications inneuroregenerative medicine. ACS Biomater Sci Eng. 2021;7(12):5823–5835.doi:10.1021/acsbiomaterials.1c01226.
Burnouf T, Goubran HA. Regenerative effect of expired platelet concentrates in human therapy:an update. Transfus Apher Sci. 2022;61(1):103363. doi:10.1016/j.transci.2022.103363.
Demir E A, Karagoz M. Platelet-Rich Plasma (PRP) is a Potential Self-Sourced CognitionBooster in Elderly Mice. Exp Aging Res, 2020;46(2), 139-153.
Ji L, Jin RJ, Li L. Platelet-rich Plasma Improves Radiotherapy-induced Emotional Disorder andCognitive Dysfunction, Neuroinflammation in Aged Rats by Inhibiting the Activation ofNLRP3 Inflammasomes. Neurochemical research. 2023;48(8):2531-41.
Liu Q, Peng S, Guo Y, et al. Social isolation, loneliness, and the onset and progression ofdepression and anxiety: The mediating role of peripheral immune biomarkers.Psychoneuroendocrinology. 2026;192:107977.
Lombardo, Sonia M., et al. "Key for crossing the BBB with nanoparticles: the rational design."Beilstein journal of nanotechnology 11.1 (2020): 866-883.
About the Contributors
